ID23771A - Turunan epotilon - Google Patents
Turunan epotilonInfo
- Publication number
- ID23771A ID23771A IDW20000002A ID20000002A ID23771A ID 23771 A ID23771 A ID 23771A ID W20000002 A IDW20000002 A ID W20000002A ID 20000002 A ID20000002 A ID 20000002A ID 23771 A ID23771 A ID 23771A
- Authority
- ID
- Indonesia
- Prior art keywords
- alkyl
- group
- substituted
- aryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5195197P | 1997-07-08 | 1997-07-08 | |
US6752497P | 1997-12-04 | 1997-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ID23771A true ID23771A (id) | 2000-05-11 |
Family
ID=26729990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IDW20000002A ID23771A (id) | 1997-07-08 | 1998-06-16 | Turunan epotilon |
Country Status (33)
Country | Link |
---|---|
US (10) | US6605599B1 (id) |
EP (4) | EP1526133A1 (id) |
JP (2) | JP4090514B2 (id) |
KR (1) | KR100569041B1 (id) |
CN (1) | CN100384834C (id) |
AR (1) | AR013358A1 (id) |
AT (2) | ATE309236T1 (id) |
AU (1) | AU731497B2 (id) |
BG (1) | BG64952B1 (id) |
BR (1) | BRPI9810555A8 (id) |
CA (1) | CA2296012C (id) |
CO (1) | CO4940501A1 (id) |
CZ (1) | CZ297904B6 (id) |
DE (2) | DE69832294T2 (id) |
DK (1) | DK1019389T3 (id) |
EE (1) | EE04566B1 (id) |
EG (1) | EG24464A (id) |
ES (2) | ES2251088T3 (id) |
GE (1) | GEP20032897B (id) |
HK (2) | HK1026905A1 (id) |
HU (1) | HU227444B1 (id) |
ID (1) | ID23771A (id) |
IL (1) | IL133613A (id) |
LV (1) | LV12569B (id) |
MY (1) | MY124151A (id) |
NO (1) | NO322494B1 (id) |
NZ (1) | NZ501198A (id) |
PE (1) | PE104599A1 (id) |
PL (1) | PL197404B1 (id) |
RO (1) | RO120340B1 (id) |
TR (1) | TR200000065T2 (id) |
TW (1) | TW562802B (id) |
WO (1) | WO1999002514A2 (id) |
Families Citing this family (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
AU753546B2 (en) | 1996-11-18 | 2002-10-24 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
IL134419A0 (en) | 1997-08-09 | 2001-04-30 | Schering Ag | Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same |
US6365749B1 (en) * | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
US6380395B1 (en) * | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6498257B1 (en) * | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
JP4662635B2 (ja) | 1998-11-20 | 2011-03-30 | コーサン バイオサイエンシーズ, インコーポレイテッド | エポチロンおよびエポチロン誘導体を生成するための組換え方法および材料 |
AU2795000A (en) * | 1998-12-22 | 2000-07-12 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
PL350190A1 (en) * | 1999-02-11 | 2002-11-18 | Schering Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
EP3222619A1 (en) | 1999-04-15 | 2017-09-27 | Bristol-Myers Squibb Holdings Ireland | Cyclic protein tyrosine kinase inhibitors |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
DE10020899A1 (de) * | 2000-04-20 | 2001-10-25 | Schering Ag | 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
US6489314B1 (en) | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US20020045609A1 (en) * | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
IL155306A0 (en) | 2000-10-13 | 2003-11-23 | Univ Mississippi | Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby |
CZ20032021A3 (cs) | 2001-01-25 | 2004-05-12 | Bristol@Myersásquibbácompany | Způsoby podávání analogů epothilonu při léčbě rakoviny |
WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
CA2434526C (en) * | 2001-01-25 | 2011-11-01 | Bristol Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
CN1489466A (zh) * | 2001-01-25 | 2004-04-14 | ����˹�ж�-����˹˹������˾ | 包含埃博霉素类似物的非肠道制剂 |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
IL156988A0 (en) | 2001-02-20 | 2004-02-08 | Bristol Myers Squibb Co | Pharmaceutical compositions containing epothilone derivatives |
KR20040028720A (ko) | 2001-02-20 | 2004-04-03 | 브리스톨-마이어스스퀴브컴파니 | 치료불응성 종양 치료용 에포틸론 유도체 |
IL157312A0 (en) | 2001-02-27 | 2004-02-19 | Biotechnolog Forschung Gmbh | Processes for the preparation of epothilone derivatives and compounds produced thereby |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
WO2002098868A1 (en) | 2001-06-01 | 2002-12-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
EP1469847A1 (en) | 2002-01-14 | 2004-10-27 | Novartis AG | Combinations comprising epothilones and anti-metabolites |
EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
SI1483251T1 (sl) | 2002-03-12 | 2010-03-31 | Bristol Myers Squibb Co | C cian epotilonski derivati |
AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
AU2003243561A1 (en) | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
DE10232094A1 (de) * | 2002-07-15 | 2004-02-05 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | 5-Thiaepothilone und 15-disubstituierte Epothilone |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2004018478A2 (en) * | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
KR101406635B1 (ko) | 2002-09-23 | 2014-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | 에포틸론 b의 제조, 분리 및 정제 방법, 및 에포틸론 b의 x-선 결정 구조 |
WO2004032923A1 (en) * | 2002-10-11 | 2004-04-22 | Dana-Farber Cancer Institute Inc | Epothilone derivatives for the treatment of multiple myeloma |
AU2003302084A1 (en) | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
AU2003296242A1 (en) * | 2002-11-28 | 2004-06-18 | Wolfgang Richter | Thia-epothilone derivatives for the treatment of cancer |
EP1572193A1 (en) * | 2002-12-09 | 2005-09-14 | Novartis AG | Microtubule stabilisers for treating stenosis in stents |
GB0230024D0 (en) * | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
CN101177425B (zh) * | 2003-01-28 | 2012-07-18 | 北京华昊中天生物技术有限公司 | 一类新型埃坡霉素化合物及其制备方法和用途 |
DE602004028907D1 (de) | 2003-02-06 | 2010-10-14 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AU2008200555C1 (en) * | 2003-03-14 | 2011-12-15 | Novartis Ag | Treatment of proliferative diseases with epothilone derivatives and radiation |
US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
DE10344882A1 (de) * | 2003-09-26 | 2005-04-21 | Morphochem Ag Komb Chemie | Neue Makrocyclen zur Behandlung von Krebserkrankungen |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
WO2005054429A2 (en) * | 2003-11-19 | 2005-06-16 | The University Of Mississippi | Synthesis of the c1-c6 keto-acid synthon of the epothilones |
US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
EP1559447A1 (en) * | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
WO2006017761A2 (en) * | 2004-08-05 | 2006-02-16 | Emory University | Epothilone analogues as therapeutic agents |
EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
WO2006055742A1 (en) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
AR052142A1 (es) | 2004-11-18 | 2007-03-07 | Bristol Myers Squibb Co | Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
JP2008536479A (ja) | 2005-02-11 | 2008-09-11 | ユニバーシティ オブ サザン カリフォルニア | ジスルフィド架橋を有するタンパク質の発現法 |
CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
CA2647565A1 (en) | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | composto de ligação de domìnio bir da iap |
BRPI0718360A2 (pt) | 2006-12-04 | 2013-11-12 | Univ Illinois | "composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg" |
EP2114429A4 (en) | 2007-02-08 | 2010-05-19 | Univ Illinois | COMPOSITIONS AND METHODS FOR PREVENTING CANCER WITH CUPREDOXINS |
US8143415B2 (en) | 2007-05-25 | 2012-03-27 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
US20090076099A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched ixabepilone |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
KR20100100949A (ko) * | 2008-01-08 | 2010-09-15 | 브리스톨-마이어스 스큅 컴퍼니 | 증식성 질환의 치료를 위한 튜불린 조정제와 항-ctla4 항체의 조합물 |
BRPI0911482A2 (pt) * | 2008-04-24 | 2017-08-29 | Bristol Myers Squibb Co | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer |
US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
JP4500951B1 (ja) * | 2009-08-07 | 2010-07-14 | 学校法人神戸学院 | Dna合成酵素阻害剤 |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
AP2012006294A0 (en) | 2009-11-05 | 2012-06-30 | Rhizen Pharmaceuticals Sa | Novel kinase modulators. |
SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
CN103068824B (zh) | 2010-05-17 | 2017-09-08 | 印蔻真治疗公司 | 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物 |
CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
KR20130086534A (ko) | 2010-06-01 | 2013-08-02 | 플러스 케미칼스, 에스.에이. | 익사베필론의 고체 형태 |
CN101906099A (zh) * | 2010-07-16 | 2010-12-08 | 泰州市今朝伟业精细化工有限公司 | 一种埃博霉素d-内酰胺衍生物化学合成方法 |
MX356514B (es) | 2011-01-20 | 2018-05-30 | Univ Texas | Marcadores de formación de imagen por resonancia magnética, sistemas de suministro y extracción, y métodos de fabricación y uso de los mismos. |
KR20140033027A (ko) * | 2011-04-01 | 2014-03-17 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 안정화된 산 증폭제 |
WO2012135278A2 (en) * | 2011-04-01 | 2012-10-04 | The Research Foundation Of State University Of New York | Olefin-triggered acid amplifiers |
WO2012151525A1 (en) | 2011-05-04 | 2012-11-08 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of protein kinases |
EP2717884A1 (en) | 2011-06-06 | 2014-04-16 | Chevron Phillips Chemical Company LP | Use of metallocene compounds for cancer treatment |
EP3228325A1 (en) | 2011-06-10 | 2017-10-11 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
WO2013008091A1 (en) * | 2011-07-13 | 2013-01-17 | Xellia Pharmaceuticals Aps | Manufacturing of epothilone derivatives and the use thereof |
ES2458220T3 (es) | 2011-09-12 | 2014-04-30 | Agfa-Gevaert | Métodos para el marcado por láser color de precursores de documento de seguridad |
CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
BR112014024251A8 (pt) | 2012-03-30 | 2018-01-23 | Rhizen Pharmaceuticals S A | novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met |
WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
US9725477B2 (en) | 2012-11-17 | 2017-08-08 | Beijing Fswelcome Technology Development Co., Ltd | Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
US9309259B2 (en) | 2013-03-08 | 2016-04-12 | Scinopharm Taiwan, Ltd. | Process for ixabepilone, and intermediates thereof |
US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
CA2914742A1 (en) | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception |
US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | ポリペプチドの酵素的結合 |
JP6427564B2 (ja) | 2013-10-11 | 2018-11-21 | アサナ・バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー | タンパク質−ポリマー−薬物共役体 |
EP3054991B1 (en) | 2013-10-11 | 2019-04-03 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US10341459B2 (en) | 2015-09-18 | 2019-07-02 | International Business Machines Corporation | Personalized content and services based on profile information |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
EP3474901A1 (en) | 2016-06-27 | 2019-05-01 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
CN111315414A (zh) | 2017-06-22 | 2020-06-19 | 梅尔莎纳医疗公司 | 产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
EP3787691A1 (en) | 2018-05-04 | 2021-03-10 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
WO2019212357A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
JP2022513400A (ja) | 2018-10-29 | 2022-02-07 | メルサナ セラピューティクス インコーポレイテッド | ペプチド含有リンカーを有するシステイン操作抗体-薬物コンジュゲート |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
JP2022537543A (ja) | 2019-06-17 | 2022-08-26 | タグワークス ファーマシューティカルス ビー.ブイ. | 高速で且つ効率的なクリック放出の為の化合物 |
IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
WO2021142202A1 (en) | 2020-01-10 | 2021-07-15 | R-Pharm Us Operating Llc | Compositions of ixabepilone |
CN118339280A (zh) | 2021-09-06 | 2024-07-12 | 维拉克萨生物技术有限责任公司 | 用于真核生物中遗传密码子扩展的新型氨酰tRNA合成酶变体 |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
CA3239713A1 (en) | 2021-12-08 | 2023-06-15 | Edward A. LEMKE | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
EP4314031B1 (en) | 2022-02-15 | 2024-03-13 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
WO2024080872A1 (en) | 2022-10-12 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4272525A (en) | 1978-10-23 | 1981-06-09 | Schering Corporation | Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them |
IL69666A (en) | 1982-09-13 | 1987-10-20 | Lilly Co Eli | 20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use |
US4820695A (en) | 1982-09-13 | 1989-04-11 | Eli Lilly And Company | C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
JPH03101679A (ja) | 1989-09-14 | 1991-04-26 | Sankyo Co Ltd | リゾキシン誘導体 |
US5798345A (en) | 1990-09-21 | 1998-08-25 | Bone Care International, Inc. | Method of inhibiting the hyperproliferation of malignant cells |
US5789397A (en) | 1991-01-08 | 1998-08-04 | Bone Care International, Inc. | Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2 |
ZA923125B (en) | 1991-05-02 | 1993-10-29 | Elil Lilly And Company | Treatment of mastitis |
US5217960A (en) | 1991-05-03 | 1993-06-08 | Abbott Laboratories | Erythromycin derivatives |
JP3101679B2 (ja) | 1991-07-02 | 2000-10-23 | 株式会社ニチレイ | 動物細胞の凍結保存用血清不含培地及び保存方法 |
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
US5795882A (en) | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
TW226373B (id) | 1992-07-15 | 1994-07-11 | Pfizer | |
EP0586738A1 (en) | 1992-09-11 | 1994-03-16 | Boehringer Ingelheim Vetmedica Gmbh | Enhanced chemotherapeutic compositions against microbial infections in fish containing a benzylamine derivative and an antimicrobial substance |
CZ276893A3 (en) | 1992-12-21 | 1994-07-13 | Lilly Co Eli | Pharmaceutical preparation for treating gramm-positive disease even of water animals |
AU6019794A (en) | 1993-03-18 | 1994-10-11 | Pfizer Inc. | Antibacterial 16-membered ring macrolides containing olefins at c-20 |
DE4316836A1 (de) | 1993-05-19 | 1994-11-24 | Knoell Hans Forschung Ev | Tetrahydrofuranyl-propionsäure, ein Verfahren zu ihrer Herstellung und Verwendung derselben |
US5716939A (en) | 1993-07-15 | 1998-02-10 | Pfizer Inc. | Amide derivatives of 16-membered ring antibiotic macrolides |
SG49853A1 (en) | 1993-08-16 | 2001-07-24 | Novartis Ag | Novel macrolides and the use thereof |
US5763429A (en) | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
AU3121095A (en) | 1994-09-22 | 1996-04-09 | Pfizer Inc. | Antibiotic macrolides |
AU3953595A (en) | 1994-10-07 | 1996-05-02 | Merck & Co., Inc. | Process for assessing tubulin protein polymerization |
IL117200A0 (en) | 1995-02-21 | 1996-06-18 | Schering Ag | Diethylenetriamine-pentaacetic acid monoamide derivatives pharmaceutical compostions containing the same and processes for the preparation thereof |
US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
US5515936A (en) * | 1995-07-10 | 1996-05-14 | Vehicules Ts Bellechasse Ltee | Track tensioning system for endless track propelled vehicle |
DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
ATE218556T1 (de) | 1995-11-17 | 2002-06-15 | Biotechnolog Forschung Gmbh | Epothilon-derivate und deren herstellung |
WO1997019088A1 (en) | 1995-11-21 | 1997-05-29 | Hoechst Celanese Corporation | Novel nonlinear optical molecules and polymers incorporating them |
EP0778283A3 (en) | 1995-12-05 | 1998-01-28 | Pfizer Inc. | Antibiotic macrolides |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
GB9623944D0 (en) | 1996-11-15 | 1997-01-08 | Zeneca Ltd | Bicyclic amine derivatives |
AU753546B2 (en) | 1996-11-18 | 2002-10-24 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
AT404477B (de) | 1997-01-15 | 1998-11-25 | Thal Hermann Dipl Ing | Gebündeltes spannglied und verfahren zur herstellung desselben |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
CN1544436A (zh) | 1997-02-25 | 2004-11-10 | ���\���о�����˾��GBF�� | 3,7-保护的环氧噻嗪酮-n-氧化物及其制备方法 |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
JP4065573B2 (ja) | 1997-04-18 | 2008-03-26 | ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
ES2184307T3 (es) | 1997-07-16 | 2003-04-01 | Schering Ag | Derivados de tiazol, procedimiento para su preparacion y su utilizacion. |
IL134419A0 (en) | 1997-08-09 | 2001-04-30 | Schering Ag | Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
SI1052974T1 (sl) | 1998-02-05 | 2009-10-31 | Novartis Ag | Farmacevtska formulacija, ki vsebuje epotilon |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
US6136630A (en) * | 1998-06-04 | 2000-10-24 | The Regents Of The University Of Michigan | Method of making a micromechanical device from a single crystal semiconductor substrate and monolithic sensor formed thereby |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
JP4662635B2 (ja) | 1998-11-20 | 2011-03-30 | コーサン バイオサイエンシーズ, インコーポレイテッド | エポチロンおよびエポチロン誘導体を生成するための組換え方法および材料 |
AU2795000A (en) | 1998-12-22 | 2000-07-12 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
US6610736B1 (en) | 1999-02-18 | 2003-08-26 | Schering Ag | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
CZ20032021A3 (cs) | 2001-01-25 | 2004-05-12 | Bristol@Myersásquibbácompany | Způsoby podávání analogů epothilonu při léčbě rakoviny |
WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
CN1489466A (zh) | 2001-01-25 | 2004-04-14 | ����˹�ж�-����˹˹������˾ | 包含埃博霉素类似物的非肠道制剂 |
IL156988A0 (en) | 2001-02-20 | 2004-02-08 | Bristol Myers Squibb Co | Pharmaceutical compositions containing epothilone derivatives |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
US7026362B2 (en) | 2001-10-09 | 2006-04-11 | Simax Technologies, Inc. | Sol-gel process utilizing reduced mixing temperatures |
-
1998
- 1998-05-26 US US09/084,542 patent/US6605599B1/en not_active Ceased
- 1998-06-16 EP EP04028580A patent/EP1526133A1/en not_active Withdrawn
- 1998-06-16 EP EP04028581A patent/EP1531153A1/en not_active Withdrawn
- 1998-06-16 IL IL13361398A patent/IL133613A/xx not_active IP Right Cessation
- 1998-06-16 AU AU79720/98A patent/AU731497B2/en not_active Ceased
- 1998-06-16 CA CA002296012A patent/CA2296012C/en not_active Expired - Lifetime
- 1998-06-16 EE EEP200000013A patent/EE04566B1/xx not_active IP Right Cessation
- 1998-06-16 WO PCT/US1998/012550 patent/WO1999002514A2/en active IP Right Grant
- 1998-06-16 EP EP04021059A patent/EP1493738B1/en not_active Expired - Lifetime
- 1998-06-16 CZ CZ20000058A patent/CZ297904B6/cs not_active IP Right Cessation
- 1998-06-16 HU HU0103111A patent/HU227444B1/hu not_active IP Right Cessation
- 1998-06-16 DE DE69832294T patent/DE69832294T2/de not_active Expired - Lifetime
- 1998-06-16 EP EP98930300A patent/EP1019389B1/en not_active Expired - Lifetime
- 1998-06-16 RO RO99-01332A patent/RO120340B1/ro unknown
- 1998-06-16 NZ NZ501198A patent/NZ501198A/en not_active IP Right Cessation
- 1998-06-16 ID IDW20000002A patent/ID23771A/id unknown
- 1998-06-16 ES ES98930300T patent/ES2251088T3/es not_active Expired - Lifetime
- 1998-06-16 AT AT98930300T patent/ATE309236T1/de active
- 1998-06-16 PL PL338003A patent/PL197404B1/pl unknown
- 1998-06-16 JP JP50867399A patent/JP4090514B2/ja not_active Expired - Fee Related
- 1998-06-16 CN CNB988069067A patent/CN100384834C/zh not_active Expired - Fee Related
- 1998-06-16 DK DK98930300T patent/DK1019389T3/da active
- 1998-06-16 TR TR2000/00065T patent/TR200000065T2/xx unknown
- 1998-06-16 AT AT04021059T patent/ATE426598T1/de not_active IP Right Cessation
- 1998-06-16 GE GEAP19985171A patent/GEP20032897B/en unknown
- 1998-06-16 BR BRPI9810555A patent/BRPI9810555A8/pt active Search and Examination
- 1998-06-16 KR KR1020007000120A patent/KR100569041B1/ko active IP Right Grant
- 1998-06-16 ES ES04021059T patent/ES2322807T3/es not_active Expired - Lifetime
- 1998-06-16 DE DE69840693T patent/DE69840693D1/de not_active Expired - Lifetime
- 1998-07-02 TW TW087110722A patent/TW562802B/zh not_active IP Right Cessation
- 1998-07-07 EG EG79298A patent/EG24464A/xx active
- 1998-07-07 PE PE1998000604A patent/PE104599A1/es not_active Application Discontinuation
- 1998-07-07 CO CO98038387A patent/CO4940501A1/es unknown
- 1998-07-08 MY MYPI98003121A patent/MY124151A/en unknown
- 1998-07-08 AR ARP980103322A patent/AR013358A1/es active IP Right Grant
-
2000
- 2000-01-07 NO NO20000076A patent/NO322494B1/no not_active IP Right Cessation
- 2000-01-10 BG BG104068A patent/BG64952B1/bg unknown
- 2000-02-02 LV LVP-00-17A patent/LV12569B/en unknown
- 2000-09-26 HK HK00106086A patent/HK1026905A1/xx not_active IP Right Cessation
-
2001
- 2001-04-02 HK HK01102362.5A patent/HK1031731A1/xx not_active IP Right Cessation
-
2003
- 2003-04-03 US US10/405,886 patent/US7125899B2/en not_active Expired - Lifetime
-
2006
- 2006-08-30 US US11/512,623 patent/US7241755B2/en not_active Expired - Lifetime
-
2007
- 2007-06-13 JP JP2007156260A patent/JP4885067B2/ja not_active Expired - Fee Related
- 2007-06-15 US US11/763,636 patent/US8536327B2/en not_active Expired - Fee Related
-
2009
- 2009-08-11 US US12/539,492 patent/USRE41911E1/en not_active Expired - Lifetime
- 2009-08-11 US US12/539,496 patent/USRE41895E1/en not_active Expired - Lifetime
- 2009-08-11 US US12/539,498 patent/USRE41893E1/en not_active Expired - Lifetime
-
2010
- 2010-09-15 US US12/882,769 patent/USRE43003E1/en not_active Expired - Fee Related
-
2013
- 2013-08-14 US US13/966,613 patent/US8921542B2/en not_active Expired - Fee Related
-
2014
- 2014-11-25 US US14/553,081 patent/US20150080440A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ID23771A (id) | Turunan epotilon | |
ATE153341T1 (de) | 5-o-desosaminylerythronolid derivate | |
ATE191481T1 (de) | Indolderivate als 5-ht1-like agonisten | |
HUP9901155A2 (hu) | Kinazolinszármazékok mint VEGF-inhibítorok | |
DE69231834D1 (de) | Pyrrolidylthiocarbapenemderivat mit antibakterieller Wirkung | |
DE69029627D1 (de) | 4-(1'-Oxocyclohex-2'-yl)azetidin-2-on-Derivate | |
SE8303910L (sv) | 15-deoxi-hydroxiprostaglandiner och forfarande for framstellning derav | |
NO893453L (no) | Antibakterielle spiro-forbindelser og fremgangsmaate for deres fremstilling. | |
NO942758L (no) | Benzopyraner og beslektede LTB4 antagonister | |
DE3879258D1 (de) | Praeparat gegen ulcus. | |
DE69024397D1 (de) | Diaminoethylen-Verbindungen | |
FI912899A (fi) | Foerfarande foer framstaellning av hexahydroazepinderivat. | |
SE7711836L (sv) | Nya 8-azapurin-6-oner | |
ES2065994T3 (es) | Beta-dicetonas substituidas. | |
IE800410L (en) | 1,2,4-triazoles. | |
DK221490D0 (da) | Beta-carbonyl-carboxyamider af 1,3-thiazolidiner | |
DK0427694T3 (da) | Syntese af mannojirimycin-derivater | |
SE8103107L (sv) | Forfarande for framstellning av 4a-aryl-oktahydro-1h-2-pyrindiner | |
IE900215L (en) | BENZO (b) PYRANS | |
FI811201L (fi) | 4-hydroxi-1,2-benzisotiazol-3(2h)-on-1,1-dioxid deras salter deras framstaellning och anvaendning | |
TH51746A (th) | อนุพันธ์เอโพไธโลน (Epothilone) | |
TH52029B (th) | อนุพันธ์เอโพไธโลน (Epothilone) | |
HUP9902439A2 (hu) | Prenil-transzferáz inhibitor hatású tiazolidinszármazékok, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények |